Radiopharmaceutical CDMO/CMO Services Market Top Companies Study - PharmaLogic, Eckert & Ziegler, AtomVie, Eczacıbaşı-Monrol.

Radiopharmaceutical CDMO/CMO Services Market Size is valued at USD 2.9 Billion in 2024 and is predicted to reach USD 7.0 Billion by the year 2034 at a 9.2% CAGR during the forecast period for 2025-2034.

Global Radiopharmaceutical CDMO/CMO Services Market 2025-2034 full Research Repot latest version is now available.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2472

Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global radiopharmaceutical CDMO/CMO services market are:
• Growing prevalence of cancer
• Growing interest in personalized treatment
• Technological advancements

The following are the primary obstacles to the radiopharmaceutical CDMO/CMO services market's expansion:
• High cost
• Inadequate infrastructure
• Shortages of skilled workers

Future expansion opportunities for the global radiopharmaceutical CDMO/CMO services market include:
• Growing use of nuclear therapy in underdeveloped nations
• Increasing investments in research and development
• Increased partnership with pharmaceutical industries

Key Industry Insights & Findings from the report:
• The market is growing rapidly due to supportive government initiatives and technological advancements.
• The market for radiopharmaceutical CDMO/CMO services is driven by the increasing incidence of cancer and pharmaceutical firms outsourcing manufacturing to save costs and comply with regulations.
• North America dominated the market and accounted for a revenue share of global revenue in 2023.
• High costs and lack of infrastructure are major issues impeding industry expansion.

Market Analysis:
The radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services market is experiencing robust growth, primarily driven by the increasing incidence of cardiovascular diseases and cancer, along with a rising demand for nuclear-based therapies and advancements in radiopharmaceutical technologies. Additionally, strong governmental support, elevated research and development expenditures, and the continued evolution of medical imaging applications are significantly contributing to market expansion. The growing emphasis on personalized medicine and the ongoing requirement for tailored therapeutic solutions further support the increasing adoption of radiopharmaceutical contract development and manufacturing services.

List of Prominent Players in the Radiopharmaceutical CDMO/CMO Services Market:
• Minerva Imaging
• Evergreen Theragnostics, Inc.
• NMR (NorthStar Medical Radioisotopes
• PharmaLogic
• Eckert & Ziegler
• AtomVie
• Eczacıbaşı-Monrol
• Cardinal Health
• Nucleus RadioPharma
• Seibersdorf Labor GmbH
• Global Medical Solutions
• SOFIE
• SpectronRx
• Agilera Pharma AS
• Siemens Healthineers
• Grupo RPH
• Almac Group
• Medi-Radiopharma
• Itm Radiopharma
• Nihon Medi-Physics Co., Ltd.
• IONETIX Corporation
• GBI
• DuchemBio, Co., Ltd

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Recent Developments:
• In February 2024, the clinical-stage radiopharmaceutical company Evergreen Theragnostics, Inc. announced that it has partnered and licensed with the Medical University of Innsbruck, a preeminent European research institution, to promote the development of innovative radiopharmaceuticals.
• In February 2025, Lantheus Holdings, Inc. announced a definitive agreement to acquire Evergreen Theragnostics, Inc. ("Evergreen") in an all-cash transaction that includes a $250 million upfront payment and up to an additional $752.5 million in potential milestone payments. The company is dedicated to helping clinicians Find, Fight, and Follow disease to improve patient outcomes.
• In October 2024, Atley Solutions delivered and installed the first commercial unit at Minerva Imaging's facilities in Denmark, following the regulatory approval and launch of the world's first commercial module for making Astatine-211 (At-211) radiopharmaceuticals. With the release of the Atley C100, Atley Solutions has achieved a major technical and business milestone, solidifying its position as a world leader in commercial products and services for At-211 radiopharmaceuticals.

Radiopharmaceutical CDMO/CMO Services Market Dynamics:
Market Drivers: Technological Advancements
The expansion of the radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services market is largely attributed to ongoing technological advancements. Innovations in artificial intelligence (AI)-driven imaging, automated radiopharmaceutical production, and the evolution of nuclear medicine technologies are significantly enhancing the precision and efficacy of treatments. Progress in drug formulation, the introduction of novel isotopes, and the development of personalized radiotherapies are further improving therapeutic outcomes. Moreover, advancements in quality assurance, regulatory compliance, and radiopharmaceutical synthesis are streamlining production processes, thereby supporting continued market growth.

Challenges: High Operational Costs
The growth of the radiopharmaceutical CDMO/CMO services market is hindered by substantial operational costs. These include high expenses related to raw materials, complex and highly regulated production processes, and specialized logistics due to the short half-life of radioisotopes. The requirement for purpose-built facilities, skilled personnel, radiation safety measures, and stringent quality control systems further increases the financial burden. These factors collectively limit the scalability and accessibility of services, posing challenges to broader market expansion.

Regional Outlook: North America
North America is anticipated to lead the radiopharmaceutical CDMO/CMO services market, demonstrating the highest compound annual growth rate (CAGR) over the forecast period. This growth is driven by rising demand for nuclear medicine, increasing prevalence of cancer and cardiovascular diseases, and significant investment in research and development within the radiopharmaceutical sector. The region benefits from a well-established healthcare infrastructure, supportive regulatory frameworks, and substantial governmental backing. Furthermore, the presence of major pharmaceutical firms, specialized CDMOs, and continuous innovations in targeted radiotherapies are expected to sustain and accelerate market growth in North America.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2472

Segmentation of Radiopharmaceutical CDMO/CMO Services Market-
By Application-
• Diagnostic Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals
By Type of Radioisotope-
• Technetium-99m
• Fluorine-18
• Leutetium-177
• Gallium-68
• Actinium-225
• Others
By Source of Manufacturing-
• Nuclear Reactors
• Cyclotrons
By Scale of Operation-
• Preclinical
• Clinical
• Commercial
By Therapeutic Area-
• Cardiovascular Disorders
• Neurological Disorders
• Oncological Disorders
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/radiopharmaceutical-cdmocmo-services-market/2472

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.